Drugs in Focus
Emmanuel Mas, Osvaldo Borrelli, Ilse Broekaert, J. Martin de‐Carpi, Jernej Dolinsek, Erasmo Miele, Corina Pienar, C. Ribes Koninckx, Ruth‐Anne Thomassen, Mike Thomson, Christo Tzivinikos, Marc A. Benninga
Abstract
ABSTRACT: Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms "octreotide" and "children" and "bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility".